HDAC

Research

Could inhibiting both HDAC and PD-1 improve I-O treatments?

OnKure's HDAC inhibitor overcame resistance to anti-PD-1 therapy in mouse models of B-cell lymphoma, University of Colorado researchers found.
Arlene Weintraub Jun 24, 2019 10:30am

Viracta's combo garners high response in EBV-linked lymphoma

Jun 3, 2019 11:39am

Xynomic preps broad push for HDAC cancer drug

Jun 1, 2018 10:26am

Syndax pals up with Nektar on entinostat combo trial

May 31, 2018 10:10am

Syndax touts possible biomarker data in HDAC/PD-1 combo in NSCLC

May 17, 2018 10:29am